You are viewing the site in preview mode
Skip to main content
|
Cancer site
|
Study type
|
Treatment
|
Putative function
|
Putative mechanism
|
PubMed ID
|
|---|
|
Osteosarcoma
|
In vitro
|
Cisplatin
|
Chemoresistance
|
Through STAT3 and miR-125a-5p
|
30777616
|
|
Colorectal cancer
|
In vitro
|
5-Fluorouracil
|
Chemoresistance
|
by regulating ATP-binding cassette subfamily C member 1 through binding Let-7a
|
30279206
|
|
Lung adenocarcinoma
|
In vitro
|
Paclitaxel
|
Chemoresistance
|
Through the mitochondrial pathway by modulating the expression of apoptosis-related protein cleaved-PARP and Bcl-2
|
28402932
|
|
Nasopharyngeal carcinoma
|
In vitro
|
Radiation
|
Radioresistance
|
Via functioning as a miR-125a sponge
|
28402230
|
|
In vitro
|
Cisplatin
|
Chemoresistance
|
Via regulating microRNA let-7a
|
28117929
|
|
Multiple myeloma
|
Patients
|
Hematopoietic stem cell transplantation
|
Relapse
|
By modulating p14ARF-MDM2-p53 axis
|
28150872
|
|
Gastric cancer
|
In vitro
|
Cisplatin and 5-fluorouracil
|
Multidrug resistance
|
Decreased the expression of MDR1 and MRP1
|
27121324
|
|
Bladder cancer
| |
Gemcitabine
|
Resistance
|
Through the Wnt signaling pathway
|
29937935
|
|
laryngeal squamous cell cancer
| |
Cisplatin and paclitaxel
| |
CDKN2B-AS1 expression decrease
|
25257554
|
|
Oral squamous cancer
| |
Cisplatin
|
Resistance
|
Via impairment of the drug transporters MRP1 and ABCC2
|
29176691
|
